AHSNs partner with the BMS-Pfizer Alliance for stroke prevention in atrial fibrillation competitive grant scheme

Posted on 17 July 2017 (Permalink)


The BMS-Pfizer Alliance has announced a partnership with the AHSN Network to provide independent grant support to organisations for healthcare quality improvement and education in the area of atrial fibrillation.

Pfizer’s Independent Grants for Learning and Change (IGLC) programme aims to establish a grant scheme to fund projects that aim to improve the identification and management of atrial fibrillation (to prevent stroke) and venous thromboembolism, with a focus on service evaluation, medical education and quality improvement projects. 

The mission of Pfizer’s Office for IGLC is to partner with the global healthcare community to improve patient outcomes in areas of mutual interest through support of measurable learning and change strategies. 

During 2017, the AHSN Network and the BMS-Pfizer Alliance will enter into a joint agreement to deliver an IGLC programme. The Network and the alliance will jointly issue a Request for Proposals (RFP) that describes the clinical practice areas that they hope to address with available grant funding. Successful applications should aim to meet such identified clinical gaps. 

During 2016, BMS and Pfizer partnered with the AHSN Network in a similar joint quality improvement programme to improve the care of patients with atrial fibrillation. 13 proposals were received and these were assessed by an expert review panel convened by AHSNs. Five projects were selected and have now been funded through this programme, with a total amount funded of £478,390.

More information will be available shortly, but in the meantime, you can read more here